investorscraft@gmail.com

Intrinsic Value of Castle Biosciences, Inc. (CSTL)

Previous Close$20.30
Intrinsic Value
Upside potential
Previous Close
$20.30

VALUATION INPUT DATA

This valuation is based on fiscal year data as of 2024 and quarterly data as of .

Data is not available at this time.

Stock Valuation Context

Business Model And Market Position

Castle Biosciences, Inc. operates in the diagnostics sector, specializing in genomic and molecular testing to improve patient care in dermatologic cancers and other diseases. The company generates revenue primarily through its proprietary diagnostic tests, such as DecisionDx-Melanoma and DecisionDx-SCC, which provide actionable insights for treatment planning. Castle Biosciences differentiates itself through clinically validated, high-complexity tests that address unmet medical needs, positioning it as a leader in precision diagnostics for skin cancer. The company’s focus on innovation and evidence-based solutions strengthens its competitive edge in a rapidly evolving healthcare landscape. Its tests are widely adopted by clinicians, reinforcing its market presence and supporting long-term growth in the expanding molecular diagnostics industry. By leveraging its scientific expertise and strategic collaborations, Castle Biosciences maintains a strong foothold in niche markets with high barriers to entry.

Revenue Profitability And Efficiency

Castle Biosciences reported revenue of $332.1 million for FY 2024, reflecting its ability to scale its diagnostic offerings. The company achieved net income of $18.2 million, with diluted EPS of $0.62, demonstrating improved profitability. Operating cash flow was robust at $64.9 million, supported by efficient operations and disciplined cost management. Capital expenditures of $28.3 million indicate ongoing investments in capacity and innovation.

Earnings Power And Capital Efficiency

The company’s earnings power is underscored by its ability to convert revenue into net income, with a net margin of approximately 5.5%. Operating cash flow significantly exceeds net income, highlighting strong cash generation capabilities. Capital efficiency is evident as the company balances growth investments with profitability, maintaining a lean operational structure while expanding its test portfolio.

Balance Sheet And Financial Health

Castle Biosciences maintains a solid balance sheet, with $119.7 million in cash and equivalents, providing liquidity for growth initiatives. Total debt stands at $26.3 million, indicating a conservative leverage profile. The company’s financial health is further supported by positive operating cash flow, ensuring flexibility to fund R&D and commercialization efforts without over-reliance on external financing.

Growth Trends And Dividend Policy

Revenue growth reflects increasing adoption of Castle Biosciences’ tests, driven by clinical utility and expanding indications. The company does not currently pay dividends, opting to reinvest cash flows into growth opportunities. Future trends may include geographic expansion and new product launches, supported by a strong pipeline and strategic partnerships.

Valuation And Market Expectations

The market values Castle Biosciences based on its growth potential in precision diagnostics, with investors likely pricing in future test adoption and pipeline developments. Valuation metrics should be assessed against peers in the high-growth molecular diagnostics space, where premium multiples are common due to innovation-driven upside.

Strategic Advantages And Outlook

Castle Biosciences benefits from proprietary technology, strong clinical validation, and a focused commercial strategy. The outlook remains positive, with opportunities to expand test utilization and enter new markets. Risks include reimbursement dynamics and competition, but the company’s differentiated offerings and execution track record position it well for sustained growth.

Sources

Company filings, investor presentations

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2025202620272028202920302031203220332034203520362037203820392040204120422043204420452046204720482049

INCOME STATEMENT

Revenue growth rate, %NaN
Revenue, $NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $mNaN
Operating income, $mNaN
EBITDA, $mNaN
Interest expense (income), $mNaN
Earnings before tax, $mNaN
Tax expense, $mNaN
Net income, $mNaN

BALANCE SHEET

Cash and short-term investments, $mNaN
Total assets, $mNaN
Adjusted assets (=assets-cash), $mNaN
Average production assets, $mNaN
Working capital, $mNaN
Total debt, $mNaN
Total liabilities, $mNaN
Total equity, $mNaN
Debt-to-equity ratioNaN
Adjusted equity ratioNaN

CASH FLOW

Net income, $mNaN
Depreciation, amort., depletion, $mNaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $mNaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $mNaN
Free cash flow, $mNaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $mNaN
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount